

Investigation Report on China's Infliximab Market 2022-2031

<https://marketpublishers.com/r/IBBEF7EF4BBEN.html>

Date: July 2022

Pages: 40

Price: US\$ 3,200.00 (Single User License)

ID: IBBEF7EF4BBEN

Abstracts

Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-?) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. The Chinese infliximab market is completely dominated by Janssen, a Johnson & Johnson company, until 2021. Two local Chinese companies, Taizhou Mabtech Pharmaceutical Co., Ltd. and Hisun Biopharmaceutical Co., Ltd. are launching infliximab in 2021, making Janssen's infliximab a challenge in the Chinese market.

According to CRI's market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price. After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.9% in 2020 and reached CNY335.89 million in 2021. The CAGR of infliximab's sales value in China is approximately 19.0% from 2017 to 2021.

According to CRI's market research and expert interviews, CRI sees different trends in 2022 and from 2023 to 2026 in China's infliximab market.

Sales volume and value of infliximab in China are expected to decline in 2022 as the Chinese government implements a strict "COVID-19 dynamic zeroing" policy that will prevent many healthcare facilities in China from operating normally. It is expected that the Chinese government will relax the COVID-19 control policy from early 2023 onwards, and thus the sales volume and sales value of infliximab in China will show a

recovery growth from 2023-2026.

Topics Covered:

The impact of COVID-19 on China's Infliximab market

Sales value of China's Infliximab 2017-2021

Competitive landscape of China's Infliximab market

Prices of Infliximab in China

Prices of Infliximab in China by regions and manufacturers

Analysis on factors affecting the development of China's Infliximab market

Prospect of China's Infliximab market from 2022 to 2026

Contents

1 RELEVANT CONCEPTS OF INFLIXIMAB

- 1.1 Indications for Infiximab
- 1.2 Development of Infiximab in China
- 1.3 Governmental Approval of Infiximab in China
- 1.4 The Impact of COVID-19 on Infiximab sales in China

2 SALES OF INFLIXIMAB IN CHINA, 2017-2021

- 2.1 Sales Value of Infiximab
 - 2.1.1 Overall Sales Value
 - 2.1.2 Sales Value by Region
- 2.2 Sales Volume of Infiximab
 - 2.2.1 Overall Sales Volume
 - 2.2.2 Sales Volume by Regions
- 2.3 Sales of Infiximab by Dosage Form in China, 2017-2021
 - 2.3.1 Injection
 - 2.3.2 Analysis of Other Dosage Forms

3 ANALYSIS OF MAJOR INFLIXIMAB MANUFACTURERS IN CHINA, 2017-2021

- 3.1 Analysis of Market Share of Major Infiximab Manufacturers
 - 3.1.1 Investigation on Market Share by Sales Value
 - 3.1.2 Investigation on Market Share by Sales volume
- 3.2 Janssen Biologics BV
 - 3.2.1 Enterprise Profile
 - 3.2.2 Sales of REMICADE (Janssen's Infiximab) in China

4 PRICES OF INFLIXIMAB FOR DIFFERENT MANUFACTURERS IN CHINA, 2021-2022

- 4.1 Janssen Biologics BV (REMICADE)

5 PROSPECT OF CHINESE INFLIXIMAB DRUG MARKET, 2022-2031

- 5.1 Influential Factors of Chinese Infiximab Market Development
 - 5.1.1 The Impact of COVID-19 on Chinese Infiximab Market

- 5.1.2 Market Drivers and Opportunities
- 5.1.3 Market Threats and Challenges
- 5.2 Forecast on Market Size
- 5.3 Forecast on Market Trend

List Of Charts

LIST OF CHARTS

Chart Infiximab Drugs Approved by Chinese Government, by 2022

Chart Sales Value of Infiximab in China, 2017-2021

Chart Sales Value of Infiximab in Regions of China, 2017-2021

Chart Sales Volume of Infiximab in China, 2017-2021

Chart Sales Volume of Infiximab in Regions of China,2017-2021

Chart Sales value and volume of infiximab injection in China 2017-2021

Chart Market Share of TOP3 Infiximab Manufacturers by Sales Value in China, 2017-2021

Chart Market Share of TOP3 Infiximab Manufacturers by Sales Volume in China, 2017-2021

Chart Profile of Janssen Biologics BV

Chart Sales Value of Janssen Biologics BV 's Infiximab in China, 2017-2021

Chart Sales Volume of Janssen Biologics BV 's Infiximab in China, 2017-2021

Chart Profile of Taizhou Mabtech Pharmaceutical Co., Ltd.

Chart Sales Value of Taizhou Mabtech Pharmaceutical Co., Ltd.'s Infiximab in China, 2017-2021

Chart Sales Volume of Taizhou Mabtech Pharmaceutical Co., Ltd. 's Infiximab in China, 2017-2021

Chart Hisun Biopharmaceutical Co., Ltd.

Chart Sales Value of Xi'an Hanfeng Pharmaceutical Co., Ltd.'s Infiximab in China, 2017-2021

Chart Sales Volume of Xi'an Hanfeng Pharmaceutical Co., Ltd.'s Infiximab in China, 2017-2021

Chart Prices of Janssen Biologics BV's Infiximab (Remicade®) in Parts of China, 2021-2022

Chart Prices of Taizhou Mabtech Pharmaceutical Co., Ltd.'s Infiximab (Leiting®) in Parts of China, 2021-2022

Chart Prices of Hisun Biopharmaceutical Co., Ltd.'s infiximab(Anbaite®) in Parts of China, 2021-2022

Chart Forecast on sales of infiximab in China 2022-2031

I would like to order

Product name: Investigation Report on China's Infliximab Market 2022-2031

Product link: <https://marketpublishers.com/r/IBBEF7EF4BBEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IBBEF7EF4BBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970